MannKind leaps 33% on FDA OK for Afrezza trials testing new inhaler
This article was originally published in Scrip
Executive Summary
Shares of MannKind soared as high as 33% on 12 August after the firm said the US FDA had blessed the company's design for two clinical studies aimed at evaluating the efficacy and safety of the biotech's inhaled insulin Afrezza (insulin human [rDNA origin]) using its next-generation inhaler.